Biofrontera Inc (BFRI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biofrontera Inc (BFRI) has a cash flow conversion efficiency ratio of -0.227x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.38 Million) by net assets ($10.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Biofrontera Inc to measure how many days the company can operate on defensive assets alone.
Biofrontera Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Biofrontera Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biofrontera Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biofrontera Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Clean Air Metals Inc
V:AIR
|
-0.012x |
|
Scandinavian Medical Solutions AS
CO:SMSMED
|
-0.022x |
|
Vizione Holdings Bhd
KLSE:7070
|
-0.027x |
|
Urgent.ly Inc. Common Stock
NASDAQ:ULY
|
0.038x |
|
NetX Holdings Bhd
KLSE:0020
|
0.025x |
|
MITCON Consultancy & Engineering Services Limited
NSE:MITCON
|
0.147x |
|
Multibax Public Company Limited
BK:MBAX
|
0.159x |
|
Pan Malaysia Corporation Bhd
KLSE:4081
|
0.004x |
Annual Cash Flow Conversion Efficiency for Biofrontera Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Biofrontera Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see BFRI market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $10.48 Million | $-13.36 Million | -1.275x | +44.97% |
| 2024-12-31 | $4.43 Million | $-10.27 Million | -2.317x | +55.40% |
| 2023-12-31 | $4.79 Million | $-24.89 Million | -5.194x | -665.62% |
| 2022-12-31 | $23.88 Million | $-16.20 Million | -0.678x | +71.21% |
| 2021-12-31 | $11.34 Million | $-26.71 Million | -2.356x | -11.02% |
| 2020-12-31 | $5.83 Million | $-12.37 Million | -2.122x | -270.00% |
| 2019-12-31 | $-30.18 Million | $-37.68 Million | 1.248x | -- |
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquarte… Read more